Skip to main content
. Author manuscript; available in PMC: 2010 May 13.
Published in final edited form as: Circ Res. 2007 Dec 6;102(3):328–337. doi: 10.1161/CIRCRESAHA.107.163253

Figure 2.

Figure 2

TxA2 mimetics activate AMPK via TPr in VSMCs. TPr activation causes a time-dependent AMPK activation in VSMCs (a and b). VSMCs were treated with either IBOP (1 µmol/L) or U46619 (1 µmol/L) for 5, 15, and 30 minutes. Data are means±SEM (n=4). ♣P<0.05, ‡P<0.01, treated vs control cells. VSMCs were treated with either IBOP (1 µmol/L) or U46619 (1 µmol/L) for 24 hours (c). TPr was detected at 55 and 64 kDa (Cayman’s TPr polyclonal antibody detects the TPr receptor at 55 and 64 kDa according to the production information) via Western blotting (d). The TPr antagonist SQ29548 abolishes TPr-induced AMPK activation. Confluent VSMCs were preincubated with or without the TPr antagonist SQ29548 at 1 µmol/L or 10 µmol/L for 30 minutes before being exposed to IBOP (1 µmol/L) for either 5 or 15 minutes. The blot is representative of 3 blots from 3 individual experiments.